Trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis (TRACE RA): A multicenter, randomized, placebo controlled trial
Arthritis & Rheumatology Apr 20, 2019
Kitas GD, et al. - Given a higher risk of cardiovascular event (CVE) in correlation with rheumatoid arthritis (RA), researchers examined the primary preventive value of atorvastatin vs placebo for CVE in RA patients. They performed a randomized, double-blind, placebo-controlled trial including 3002 patients aged >50 years or with RA duration >10 years; without clinical atherosclerosis, diabetes, or myopathy. Atorvastatin 40mg daily or matching placebo was administered to the patients. Outcomes support atorvastatin 40mg daily as safe in patients with RA; it resulted in significantly greater reduction of LDLc than placebo. In line with the Cholesterol Treatment Trialists’ Collaboration meta-analysis of statin effects in other populations, they identified 40% (adjusted) CVE risk reduction.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries